Pharma BD Deal Intelligence

Novartis AG / AveXis Inc.

2018 · Acquisition/Merger · $8.7B · Complete

Announcement Sentiment

Strongly positive

Outcome Score

Largely worked — most objectives met.

Novartis acquired AveXis for approximately $8.7 billion ($218 per share in cash), gaining the gene therapy AVXS-101 (later approved as Zolgensma/onasemnogene abeparvovec) for spinal muscular atrophy, along with a scalable gene therapy manufacturing platform and pipeline programs in Rett Syndrome and ALS.

Key facts

Announced Apr 09, 2018
Closed May 15, 2018
Deal value $8.7B
Deal type Acquisition/Merger
Therapeutic area Gene Therapy, Metabolic, Neurology, Rare Disease
Indications Spinal Muscular Atrophy Type 1, Spinal Muscular Atrophy Type 2, Rett Syndrome, SOD1-ALS
Key assets AVXS-101 (onasemnogene abeparvovec/Zolgensma), AVXS-201 (Rett Syndrome gene therapy), AVXS-301 (SOD1-ALS gene therapy), AAV gene therapy manufacturing platform
Mechanism AAV9-based gene replacement therapy targeting SMN1 gene

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals